In 1980, as vice-president of Systems Development of Cascade Graphics Development, Dr. Goldman developed the first microcomputer-based CAD system (prior to the well known AutoCad product).

Dr. Goldman served eight years (1995 through 2002) as Research Analyst for the Varicella Active Surveillance Project in Antelope Valley, in a cooperative project with the Centers for Disease Control and Prevention (CDC, Atlanta, GA).

Dr. Goldman has served as a reviewer many peer-reveiwed journals.

Recent Medical Publications, Abstracts, etc.
[1] The impact of vaccination on varicella incidence, conditional on school attendance and temperature, in Antelope Valley, CA. Goldman GS, Glasser JW, Maupin TJ, Peterson CL, Mascola L, Chen RT, and Seward, JF. Presentation by J.W. Glasser at 16th International Conference on Pharmacoepidemiology (ICPE); Barcelona, Spain; August 22, 2000; Pharmacoepidemiology and Drug Safety; 9(Suppl 1):S67.
[2] Varicella active surveillance: use of capture-recapture methods to assess completion of surveillance data. Peterson CL, Maupin T, Goldman G, Mascola L. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Sept. 28 - Oct. 1, 1997, Toronto, Canada; Abstract H-111, page 233.
[3] Decline in varicella incidence and hospitalizations in sentinel surveillance areas in the United States, 1995-2000. Seward J, Watson B, Peterson C, Mascola L, Pelosi J, Zhang J, Jumaan A, Maupin T, Goldman G, et al. The 4th International Conference on VZV, March 3-5, 2001, Oral Presentation, La Jolla, California. VZV Research Foundation in partnership with Columbia University College of Physicians and Surgeons.
4] Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Xhang JX, Maupin TJ, Goldman GS, et al. JAMA 2002; 287(5):606–11.
[5] Second varicella infections: are they more common than previously thought? Hall S, Maupin T, Seward J, Jumaan AO, Peterson C, Goldman G, Mascola L, Wharton M. Pediatrics. 2002 Jun;109(6):1068–73.
[6] Varicella susceptibility among adolescents in an active surveillance site. Maupin T, Goldman G, Peterson C, Mascola L, Seward J, Jumaan A, 36th National Immunization Conference of the CDC, May 1, 2002, Denver, Colorado.
[7] Varicella susceptibility and incidence of herpes-zoster among children and adolescents in a community under active surveillance. Goldman G. Vaccine, 2003 Oct. 1; 21(27-30):4238–42.
[8] Incidence of herpes-zoster among children and adolescents in a community with moderate varicella vaccination coverage. Goldman G. Vaccine, 2003 Oct. 1; 21(27-30):4243–9.
[9] Using capture-recapture methods to assess varicella incidence in a community under active surveillance. Goldman G. Vaccine, 2003 Oct 1; 21(27-30):4250–55.
[10] Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology. Goldman G. Vaccine, 2005; 23(25):3349–55.
[11] An investigation of the association between MMR vaccination and autism in Denmark. Goldman G, Yazbak EF, JAPS, Fall 2004; 9(3):70–5.
[12] Response to Letter to Editor by Jumaan: Goldman’s role in the Varicella Active Surveillance Project. Goldman GS. Vaccine, 2004; 22(25-26):3232–6.
[13] Universal varicella vaccination: Efficacy trends and effect on herpes-zoster. Goldman GS. International Journal of Toxicology, 2005 July-Aug.;24(4):205–13.
[14] The Case against Universal Varicella Vaccination. Goldman GS. International Journal of Toxicology, 2006; 25(5):313–17.
[15] Infant mortality rates regressed against number of vaccine doses routinely given: Is there a biochemical or synergistic toxicity? Miller NZ, Goldman GS. Hum Exp Toxicol., 2011 Sept.; 30(9):1420-8.
[16] Relative trends in hospitalizations and mortality among infants by number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990-2010. Goldman GS, Miller NZ. Hum Exp Toxicol 2012; 31(10):1012-21.
[17] Comparison of VAERS fetal-loss reports during three consecutive influenza seasons: Was there a synergistic fetal toxicity associated with the two-vaccine 2009/10 season? Goldman GS. Hum Exp Toxicol 2012;
[18] Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy primarily based primarily on the Antelope Valley Varicella Active Surveillance Project data. Goldman GS, King PG. Vaccine 2012;31(13):1680–94. Available online at http://dx.doi.org/10.1016/j.vaccine.2012.05.050
[19] Vaccination to prevent varicella: Goldman and King's response to Myers' interpretation of Varicella Active Surveillance Project data. Goldman GS, King P. Hum Exp Toxicol., 2014 Aug. 33(8):886–93. PMID: 24275643.